The legislation enhances transparency into PSAOs, PBMs, and pharmaceutical manufacturer pricing. It supports independent pharmacies by allowing them to be reimbursed at higher amounts and by stopping PSAOs from requiring they purchase more expensive drugs from specific wholesalers. It will lower drug costs for consumers by requiring they receive prescription drug rebates at the point of sale.